Ghayas C. Issa

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa et al. · Blood · 2022 · 71 citations

Medicine, Pharmacology, Pharmacotherapy +13

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Naval Daver, Jayastu Senapati, Abhishek Maiti et al. · Blood · 2022 · 62 citations

Medicine, Pharmacology, Pharmacotherapy +12

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Ghayas C. Issa, Branko Cuglievan, Courtney D. DiNardo et al. · Blood · 2023 · 46 citations

Medicine, Oncology, Pharmacology +15

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with <i>FLT3</i>-Mutated Acute Myeloid Leukemia

Nicholas J. Short, Courtney D. DiNardo, Naval Daver et al. · Blood · 2022 · 38 citations

Medicine, Pharmacology, Pharmacotherapy +14

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with <i>KMT2A</i>-Rearranged or <i>NPM1</i> Mutant AML: Updated Results of a Phase (Ph) 1 Study

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Blood · 2022 · 34 citations

Medicine, Molecular Biology, Pharmacology +6